Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of GSK1605786A in Crohn's disease
2010-022384-35Phase 3Terminated
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vercirnon in Crohn's disease, sponsored by GSK. Primary endpoint: Long-term safety and tolerability of GSK1605786A. Started Nov 2010; status: terminated.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-022384-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022384-35.